Blog

FDA approves the targeted therapy adagrasib for people with advanced colorectal cancer – MSKCC

Photo of Rona Yaeger from MSKCC/LinkedIn

Jun 27, 2024, 11:18

FDA approves the targeted therapy adagrasib for people with advanced colorectal cancer – MSKCC

Memorial Sloan Kettering Cancer Center shared a post on LinkedIn:

“The US Food and Drug Administration has approved the targeted therapy adagrasib in combination with another targeted therapy for people with advanced colorectal cancer caused by a gene mutation called KRAS-G12C. Dr. Rona Yaeger, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center (MSK), led the trial that resulted in this approval.

“Since we started this trial, I have had people coming to me from all over to receive this treatment,” Dr. Yaeger says. “Now that this drug combination is approved, many more patients will be able to benefit.”

Learn more here.”

Source: Memorial Sloan Kettering Cancer Center/LinkedIn

“The US Food and Drug Administration Adagrasib cancer colorectal cancer FDA KRAS G12C Memorial Sloan Kettering Cancer Center MSK MSKCC OncoDaily Oncology Rona Yaeger

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers